Avient Corp: appoints new CEO and reaffirms 2026 guidance

What happened

• The filing reports that on Oct 7, 2026 the board elected Michael J. Frank as president and chief executive officer and as a member of the board, effective Oct 7, 2026. Dr. Ashish K. Khandpur will provide advisory consulting support through 2026.
• The filing also reports that on Oct 9, 2026 the company issued a press release reaffirming its third quarter and full year 2026 financial guidance previously provided on Aug 6, 2026, and that third quarter financial closing procedures are ongoing so actual results may differ from these preliminary expectations.

Key details

• Mr. Frank, age 62, most recently served as chief executive officer of UPL Corporation Ltd and previously served as CEO of Nutrien Ag Solutions and in senior roles at Monsanto Company.
• Compensation and sign-on package for Mr. Frank includes: base salary of $1,222,000 per year; annual cash incentive target equal to 120% of base salary (prorated for 2026); long-term equity target equal to 510% of base salary for 2027; sign-on cash payment of $1,600,000 (repayable if he voluntarily resigns or is terminated for cause within 12 months); RSUs valued at approximately $5,000,000 vesting over five years (one third at year three, remainder at year five); and cash-settled performance units with a grant gate target value of approximately $11,400,000 payable 0% to 200% based on adjusted earnings per share (67%) and relative total shareholder return (33%) for Jan 1, 2026 through Dec 31, 2028.
• If Mr. Frank is terminated without Cause (and not following a change in control) and signs a release and customary non-compete/non-solicit covenants, he generally would be entitled to two years of salary continuation; an annual incentive payment as earned for the year of termination; two years of continuation in medical, dental and vision plans at subsidized rates; and up to 12 months of outplacement services.
• Under the executive severance arrangements, Dr. Khandpur is entitled to two years of salary continuation and related benefits upon satisfaction of plan conditions, and the compensation committee approved special vesting of 38,047 RSUs on Dec 1, 2026 and 38,046 RSUs on Dec 1, 2027 in exchange for his resignation from the board, advisory support through 2026 and an extension of post-employment covenants.

Why it may matter

• Item 5.02 of the filing covers the departure and election of officers and directors and provides the terms of Mr. Frank’s appointment, compensation, severance and related agreements and the arrangements for Dr. Khandpur’s transition.
• Item 2.02 of the filing covers results of operations and financial condition and states that the company reaffirmed prior Q3 and full-year 2026 guidance while noting quarter-end closing procedures are ongoing and actual results may differ.
• The filing does not show why the insider traded or why the company acted.